Company profile: Indivior
1.1 - Company Overview
Company description
- Provider of specialty pharmaceuticals focused on developing medicines for opioid use disorder (OUD). The global company works to help change patients' lives by advancing evidence-based OUD treatment and increasing access worldwide.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Indivior
Sage Therapeutics
HQ: United States
Website
- Description: Provider of novel medicines for central nervous system (CNS) disorders, focused on debilitating and disabling conditions. Offers ZURZUVAE, an oral 14-day treatment for adults with postpartum depression, and ZULRESSO, an injectable for patients 15+ with postpartum depression. Pipeline includes SAGE-689 (acute GABA hypofunction), SAGE-421 (NMDA hypofunction), and SAGE-319 (GABA hypofunction).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sage Therapeutics company profile →
Acumen Pharmaceuticals
HQ: United States
Website
- Description: Provider of targeted therapies in development for Alzheimer's disease and related neurodegenerative diseases, including ACU193, a monoclonal antibody targeting toxic soluble amyloid-beta oligomers (AβOs) for early Alzheimer's, and the INTERCEPT-AD Phase 1 trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with mild cognitive impairment or mild dementia due to Alzheimer's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acumen Pharmaceuticals company profile →
Tetra Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology therapeutics for cognitive and memory deficits. Develops BPN14770, a selective PDE4D allosteric inhibitor for Fragile X syndrome and Alzheimer’s disease; a PDE4B inhibitor to reduce inflammation and improve cognitive function in traumatic brain injury and progressive multiple sclerosis; and conducts ongoing clinical trials for memory loss treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tetra Therapeutics company profile →
Rapid Dose Therapeutics
HQ: Canada
Website
- Description: Provider of pharma-tech oral fast-dissolving drug delivery solutions, including QuickStrip for direct bloodstream delivery of pharmaceuticals and over-the-counter medicines; RDMx + QuickStrip for enabling delivery of large therapeutic molecules; Rapid Energy, Vitamin B12, and Melatonin QuickStrip products; and versions for elderly and pediatric patients needing simplified, rapid dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rapid Dose Therapeutics company profile →
Statera Spine
HQ: United States
Website
- Description: Provider of software-enabled spine imaging analytics solutions for chronic and acute spine issues, offering diagnostic and decision-making tools including Profile-ESP for standardized spinal motion and alignment data reports, and VMA, a fluoroscopy imaging system assessing spinal instability and sagittal alignment with measurements for surgical decisions and insurance disputes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Statera Spine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Indivior
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Indivior
2.2 - Growth funds investing in similar companies to Indivior
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Indivior
4.2 - Public trading comparable groups for Indivior
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →